No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.
No article has been written about this topic yet.
Be the first one to add some text.
Loading AI-assisted edit mode...
Timeline
December 1, 2020
Agenus launches phase 2 trial expansion in Colon Cancer for AGEN1181 in Combination with BalstilimabNew objective response in colon cancer triggers trial expansion.
Funding rounds
Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Products
Product
Launch date
Industry
Website
People
Name
Role
LinkedIn
Adam Hirsh
Employee
Alex Faylond
Employee
Bob Durham
Employee
Celena Toon
Employee
Christian Cortis
Employee
Christopher Clarke
Employee
Elben Guimaraes
Employee
Jacob Kung
Employee
Mike Klein
Employee
Further reading
Title
Author
Link
Type
Date
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
BioSpace
December 1, 2020
BioSpace
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the expansion of a Phase 2 trial into colon cancer based on a new objective clinical response in a colorectal cancer patient in addition to a significant tumor reduction of 27% and biomarker reduction observed i